Polymun Scientific

Executive Summary

Polymun Scientific is a specialized Austrian CDMO with over 30 years of experience in biopharmaceutical development and manufacturing, particularly in liposomal and lipid nanoparticle (LNP) formulations. Its end-to-end services from gene to clinical-grade material serve innovator and biosimilar developers, while proprietary R&D in HIV antibodies and liposomal drug delivery adds pipeline potential. The company's expertise in infectious disease and antibody development aligns with key market needs. With the growing demand for LNP-enabled therapeutics, Polymun is positioned to benefit from CDMO market expansion. Its established track record and niche capabilities could attract major contracts, though competition from larger players poses risks. Expansion of manufacturing capacity and progress in proprietary programs may drive future growth. The company remains privately held, limiting visibility, but its strategic focus offers a stable, niche opportunity.

Upcoming Catalysts (preview)

• Q4 2026Expansion of LNP manufacturing capacity70% success
• H2 2026Major CDMO contract for LNP vaccine formulation50% success
• 2026Advancement of proprietary HIV antibody program to preclinical phase40% success